Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Osteosarcoma 7Wilms Tumor 6Sarcoma 6Rhabdomyosarcoma 6Rhabdoid Tumor 6Neuroblastoma 6Lymphoma, Non-Hodgkin 6Hepatoblastoma 6Neuroectodermal Tumors, Primitive, Peripheral 5Medulloblastoma 5Histiocytosis, Langerhans-Cell 5Glioma 5Ependymoma 5Sarcoma, Ewing 4Central Nervous System Neoplasms 4Desmoid Tumors 2Xanthogranuloma, Juvenile 1Sarcoma, Synovial 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1Liposarcoma, Myxoid 1Histiocytic Sarcoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Chordoma 1Carcinosarcoma 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 20pembrolizumab 19Nivolumab 10fludarabine 7Radiosurgery 7Specimen Handling 6Ipilimumab 6Injections 5Celecoxib 5poly ICLC 4Radiation 4Paclitaxel 4Melphalan 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Docetaxel 4Cryosurgery 4durvalumab 3cemiplimab 3Filgrastim 3Etoposide 3Cisplatin 3Blood Specimen Collection 3Biopsy 3trastuzumab deruxtecan 2tislelizumab 2talimogene laherparepvec 2spartalizumab 2fludarabine phosphate 2bempegaldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Phantoms, Imaging × Sarcoma × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡